Ionis Pharmaceuticals, Inc. Investing Cash Flow
Ionis Pharmaceuticals, Inc. (IONS) reported Investing Cash Flow of $560.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $23.50M.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $536.82M, a 214.93% increase year-over-year.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$419.50M, a 714.99% decline year-over-year.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $91.34M.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$277.78M.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$134.03M.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$214.13M.
- Ionis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$262.64M, a 234.75% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $23.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $560.32M 10-Q · filed 2026-07-29 | $140.81M derived: sum of 3 quarters · filed 2026-07-29 | $232.15M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2026-03-31 | $536.82M 10-Q · filed 2026-04-29 | $117.31M derived: sum of 2 quarters · filed 2026-04-29 | $208.65M derived: sum of 3 quarters · filed 2026-04-29 | $88.58M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-12-31 | -$419.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$328.17M derived: sum of 2 quarters · filed 2026-02-26 | -$448.24M derived: sum of 3 quarters · filed 2026-07-29 | -$277.78M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $91.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$28.73M derived: sum of 2 quarters · filed 2026-07-29 | $141.73M 10-Q · filed 2025-10-29 | $209.94M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-06-30 | -$120.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $50.39M 10-Q · filed 2026-07-29 | $118.60M derived: sum of 3 quarters · filed 2026-07-29 | -$222.19M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-03-31 | $170.46M 10-Q · filed 2026-04-29 | $238.67M derived: sum of 2 quarters · filed 2026-04-29 | -$102.12M derived: sum of 3 quarters · filed 2026-04-29 | -$39.67M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2024-12-31 | $68.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$272.58M derived: sum of 2 quarters · filed 2026-02-26 | -$210.13M derived: sum of 3 quarters · filed 2026-02-26 | -$134.03M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$340.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$278.35M derived: sum of 2 quarters · filed 2025-10-29 | -$202.24M 10-Q · filed 2025-10-29 | -$228.95M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $62.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $138.56M 10-Q · filed 2025-07-30 | $111.84M derived: sum of 3 quarters · filed 2026-02-26 | $180.55M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $76.11M 10-Q · filed 2025-04-30 | $49.39M derived: sum of 2 quarters · filed 2026-02-26 | $118.10M derived: sum of 3 quarters · filed 2026-02-26 | $187.62M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | -$26.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $42.00M derived: sum of 2 quarters · filed 2026-02-26 | $111.51M derived: sum of 3 quarters · filed 2026-02-26 | -$214.13M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $68.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $138.23M derived: sum of 2 quarters · filed 2024-11-06 | -$187.41M 10-Q · filed 2024-11-06 | $24.73M derived: sum of 4 quarters · filed 2025-02-19 | |
| 2023-06-30 | $69.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$256.13M 10-Q · filed 2024-08-01 | -$43.98M derived: sum of 3 quarters · filed 2025-02-19 | -$227.91M derived: sum of 4 quarters · filed 2025-02-19 | |
| 2023-03-31 | -$325.64M 10-Q · filed 2024-05-07 | -$113.49M derived: sum of 2 quarters · filed 2025-02-19 | -$297.42M derived: sum of 3 quarters · filed 2025-02-19 | -$300.73M derived: sum of 4 quarters · filed 2025-02-19 | |
| 2022-12-31 | $212.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $28.22M derived: sum of 2 quarters · filed 2025-02-19 | $24.91M derived: sum of 3 quarters · filed 2025-02-19 | -$262.64M 10-K · filed 2025-02-19 | |
| 2022-09-30 | -$183.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$187.23M derived: sum of 2 quarters · filed 2023-11-02 | -$474.78M 10-Q · filed 2023-11-02 | -$379.67M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-06-30 | -$3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$290.85M 10-Q · filed 2023-08-09 | -$195.74M derived: sum of 3 quarters · filed 2024-02-21 | -$73.77M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-03-31 | -$287.55M 10-Q · filed 2023-05-03 | -$192.44M derived: sum of 2 quarters · filed 2024-02-21 | -$70.47M derived: sum of 3 quarters · filed 2024-02-21 | -$171.50M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2021-12-31 | $95.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $217.08M derived: sum of 2 quarters · filed 2024-02-21 | $116.05M derived: sum of 3 quarters · filed 2024-02-21 | $194.91M 10-K · filed 2024-02-21 | |
| 2021-09-30 | $121.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $20.94M derived: sum of 2 quarters · filed 2022-11-09 | $99.80M 10-Q · filed 2022-11-09 | $287.65M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-06-30 | -$101.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$22.17M 10-Q · filed 2022-08-09 | $165.68M derived: sum of 3 quarters · filed 2023-02-22 | $267.62M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-03-31 | $78.86M 10-Q · filed 2022-05-04 | $266.70M derived: sum of 2 quarters · filed 2023-02-22 | $368.64M derived: sum of 3 quarters · filed 2023-02-22 | $448.34M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2020-12-31 | $187.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $289.79M derived: sum of 2 quarters · filed 2023-02-22 | $369.48M derived: sum of 3 quarters · filed 2023-02-22 | $274.48M 10-K · filed 2023-02-22 | |
| 2020-09-30 | $101.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $181.63M derived: sum of 2 quarters · filed 2021-11-03 | $86.63M 10-Q · filed 2021-11-03 | $224.82M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-06-30 | $79.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$15.31M 10-Q · filed 2021-08-04 | $122.88M derived: sum of 3 quarters · filed 2022-02-25 | $124.28M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-03-31 | -$95.01M 10-Q · filed 2021-05-05 | $43.18M derived: sum of 2 quarters · filed 2022-02-25 | $44.58M derived: sum of 3 quarters · filed 2022-02-25 | -$66.11M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2019-12-31 | $138.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $139.59M derived: sum of 2 quarters · filed 2022-02-25 | $28.90M derived: sum of 3 quarters · filed 2022-02-25 | -$41.27M 10-K · filed 2022-02-25 | |
| 2019-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$109.29M derived: sum of 2 quarters · filed 2020-11-04 | -$179.47M 10-Q · filed 2020-11-04 | -$505.67M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | -$110.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$180.86M 10-Q · filed 2020-08-05 | -$507.07M derived: sum of 3 quarters · filed 2021-02-24 | -$814.74M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | -$70.17M 10-Q · filed 2020-05-06 | -$396.38M derived: sum of 2 quarters · filed 2021-02-24 | -$704.05M derived: sum of 3 quarters · filed 2021-02-24 | -$1.08B derived: sum of 4 quarters · filed 2021-02-24 | |
| 2018-12-31 | -$326.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$633.88M derived: sum of 2 quarters · filed 2021-02-24 | -$1.01B derived: sum of 3 quarters · filed 2021-02-24 | -$929.56M 10-K · filed 2021-02-24 | |
| 2018-09-30 | -$307.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$682.84M derived: sum of 2 quarters · filed 2019-11-06 | -$603.36M 10-Q · filed 2019-11-06 | -$657.57M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-06-30 | -$375.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$295.69M 10-Q · filed 2019-08-08 | -$349.90M derived: sum of 3 quarters · filed 2020-03-02 | -$500.00M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-03-31 | $79.49M 10-Q · filed 2019-05-09 | $25.27M derived: sum of 2 quarters · filed 2020-03-02 | -$124.83M derived: sum of 3 quarters · filed 2020-03-02 | -$110.13M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2017-12-31 | -$54.21M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$204.31M derived: sum of 2 quarters · filed 2020-03-02 | -$189.62M derived: sum of 3 quarters · filed 2020-03-02 | -$358.29M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$150.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$135.40M derived: sum of 2 quarters · filed 2018-11-06 | -$304.08M 10-Q · filed 2018-11-06 | -$283.28M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-06-30 | $14.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$153.98M 10-Q · filed 2018-08-07 | -$133.18M derived: sum of 3 quarters · filed 2019-03-01 | -$190.27M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-03-31 | -$168.68M 10-Q · filed 2018-05-07 | -$147.87M derived: sum of 2 quarters · filed 2019-03-01 | -$204.96M derived: sum of 3 quarters · filed 2019-03-01 | ||
| 2016-12-31 | $20.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$36.29M derived: sum of 2 quarters · filed 2019-03-01 | $56.60M 10-K · filed 2019-03-01 | ||
| 2016-09-30 | -$57.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $35.80M 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | $92.89M 10-Q · filed 2017-08-09 | ||||
| 2015-12-31 | -$60.05M 10-K · filed 2018-02-28 | ||||
| 2012-09-30 | -$10.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $13.49M derived: sum of 2 quarters · filed 2012-11-06 | $12.96M 10-Q · filed 2012-11-06 | $48.21M derived: sum of 4 quarters · filed 2012-11-06 | |
| 2012-06-30 | $24.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-06 | $23.57M 10-Q · filed 2012-08-06 | $58.81M derived: sum of 3 quarters · filed 2012-08-06 | $53.11M derived: sum of 4 quarters · filed 2012-11-06 | |
| 2012-03-31 | -$522.00K 10-Q · filed 2012-05-09 | $34.72M derived: sum of 2 quarters · filed 2012-05-09 | $29.02M derived: sum of 3 quarters · filed 2012-11-06 | $53.66M derived: sum of 4 quarters · filed 2012-11-06 | |
| 2011-12-31 | $35.24M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $29.54M derived: sum of 2 quarters · filed 2012-11-06 | $54.18M derived: sum of 3 quarters · filed 2012-11-06 | $110.90M 10-K · filed 2012-02-29 | |
| 2011-09-30 | -$5.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $18.94M derived: sum of 2 quarters · filed 2012-11-06 | $75.66M 10-Q · filed 2012-11-06 | $76.94M 10-Q · filed 2011-11-08 | $68.41M derived: sum of 4 quarters · filed 2012-11-06 |
| 2011-06-30 | $24.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-06 | $81.36M 10-Q · filed 2012-08-06 | $74.12M derived: sum of 3 quarters · filed 2012-08-06 | $150.03M derived: sum of 4 quarters · filed 2012-08-06 | |
| 2011-03-31 | $56.72M 10-Q · filed 2012-05-09 | $49.48M derived: sum of 2 quarters · filed 2012-05-09 | $125.39M derived: sum of 3 quarters · filed 2012-05-09 | $65.45M derived: sum of 4 quarters · filed 2012-05-09 | |
| 2010-12-31 | -$7.24M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $68.67M derived: sum of 2 quarters · filed 2012-02-29 | $8.74M derived: sum of 3 quarters · filed 2012-02-29 | $23.69M 10-K · filed 2012-02-29 | |
| 2010-09-30 | $75.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $15.98M derived: sum of 2 quarters · filed 2011-11-08 | $30.94M 10-Q · filed 2011-11-08 | $15.72M derived: sum of 4 quarters · filed 2012-02-29 | |
| 2010-06-30 | -$59.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-08 | -$44.98M 10-Q · filed 2011-08-08 | -$60.19M derived: sum of 3 quarters · filed 2012-02-29 | -$99.62M derived: sum of 4 quarters · filed 2012-02-29 | |
| 2010-03-31 | $14.96M 10-Q · filed 2011-05-06 | -$256.00K derived: sum of 2 quarters · filed 2012-02-29 | -$39.69M derived: sum of 3 quarters · filed 2012-02-29 | ||
| 2009-12-31 | -$15.21M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$54.64M derived: sum of 2 quarters · filed 2012-02-29 | -$212.29M 10-K · filed 2012-02-29 | ||
| 2009-09-30 | -$39.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-05 | -$197.08M 10-Q · filed 2010-11-05 | |||
| 2009-06-30 | -$157.65M 10-Q · filed 2010-08-09 | ||||
| 2008-12-31 | -$234.25M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |